Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a life sciences company developing a single-molecule protein analysis platform designed to advance proteomics research and drug discovery. The company became publicly traded in 2021 through a business combination with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, a healthcare-focused investment firm. As a post-merger public company, Nautilus continues to operate in the biotechnology and proteomics sector, filing its most recent quarterly report on Form 10-Q with the SEC on July 28, 2026. For comprehensive filing data, deal history, and real-time SPAC intelligence on NAUT and hundreds of other de-SPAC companies, sign up for full access at SpacDesk.